Pneumococcal dosing regimen
View Patent ↗Methods of immunizing older adult subjects against Streptococcus pneumoniae infection are provided. Provided methods comprise immunization of naïve adult subjects with a conjugated pneumococcal polysaccharide vaccine. Optionally, initial immunization may be followed by additional immunization doses comprising conjugated pneumococcal polysaccharide vaccine or unconjugated pneumococcal polysaccharide vaccine composition.
1. A method of eliciting an immunoprotective antibody response to a capsular polysaccharide of Streptococcus pneumoniae in an older subject who is 65 years or over in age, comprising administering to a first older subject who has never previously received a 23-valent unconjugated pneumococcal polysaccharide vaccine or a 7-valent pneumococcal polysaccharide conjugate vaccine an immunogenic amount of a pneumococcal polysaccharide conjugate vaccine comprising polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F conjugated to CRM 197 , wherein the antibody response for serotypes 4, 6B, 9V, 14, 18C, and 23F is higher relative to a second older subject who received a 23-valent unconjugated pneumococcal polysaccharide vaccine.
2. The method of claim 1 , further comprising administering at least one additional vaccine dose to the first subject, wherein the at least one additional vaccine dose is selected from the group consisting of a pneumococcal polysaccharide conjugate vaccine composition and an unconjugated pneumococcal polysaccharide vaccine composition.
3. The method of claim 2 , wherein the at least one additional vaccine dose is administered at least twelve months following the initial vaccine administration.
4. The method of claim 2 , wherein the at least one additional vaccine dose comprises a pneumococcal polysaccharide conjugate vaccine.
5. The method of claim 2 , wherein the at least one additional vaccine dose comprises an unconjugated pneumococcal polysaccharide vaccine composition.
6. The method of claim 1 , wherein the conjugated vaccine is selected from the group consisting of a 7-valent, 9-valent, 10-valent, 11-valent and 13-valent vaccine.
7. The method of claim 5 , wherein the unconjugated pneumococcal polysaccharide vaccine is a 23-valent pneumococcal polysaccharide vaccine.
8. The method of claim 1 , wherein the conjugated vaccine comprises polysaccharides of serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
9. The method of claim 1 , wherein the conjugated vaccine comprises polysaccharides of serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
10. The method of claim 1 , wherein the conjugated vaccine comprises polysaccharides of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9A, 9V, 14, 18C, 19F, and 23F.
11. The method of claim 7 , wherein the unconjugated vaccine comprises polysaccharides of serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
12. The method of claim 4 , wherein the conjugate vaccine comprises polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F.
13. The method of claim 4 , wherein the conjugate vaccine comprises polysaccharides of serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
14. The method of claim 4 , wherein the conjugate vaccine comprises polysaccharides of serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
15. The method of claim 4 , wherein the conjugate vaccine comprises polysaccharides of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9A, 9V, 14, 18C, 19F, and 23F.
16. The method of claim 4 , wherein the polysaccharides are conjugated to a polypeptide carrier.
17. The method of claim 16 , wherein the polypeptide carrier is selected from the group consisting of the meningococcal outer membrane protein complex, CRM 197 , diphtheria toxoid, tetanus toxoid, and protein D from H. influenzae.
18. The method of claim 12 , wherein the conjugate vaccine comprises polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F conjugated to CRM 197 .
19. A method of eliciting an immunoprotective antibody response to a capsular polysaccharide of Streptococcus pneumoniae in an older subject who is 65 years or over in age, comprising administering to a first older subject who has never previously received a 23-valent unconjugated pneumococcal polysaccharide vaccine or a 7-valent pneumococcal polysaccharide conjugate vaccine an immunogenic amount of a pneumococcal polysaccharide conjugate vaccine; and
administering to the first older subject a second dose comprising an immunogenic amount of an unconjugated pneumococcal polysaccharide vaccine,
wherein the second dose is administered at least twelve months following the first dose, wherein the pneumococcal polysaccharide conjugate vaccine comprises polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F conjugated to CRM 197 , and wherein the antibody response for serotypes 6B, 9V, 14, 18C, 19F, and 23F after the second dose is higher relative to a second older subject who received a single dose of a 23-valent unconjugated pneumococcal polysaccharide vaccine.
20. The method of claim 19 , further comprising administering at least one additional vaccine dose, wherein the at least one additional vaccine dose is selected from the group consisting of a pneumococcal polysaccharide conjugate vaccine composition and an unconjugated pneumococcal polysaccharide vaccine composition.
21. The method of claim 20 , wherein the at least one additional vaccine dose is administered at least one year after the prior dose.
22. The method of claim 20 , wherein the at least one additional vaccine dose comprises a pneumococcal polysaccharide conjugate vaccine.
23. The method of claim 20 , wherein the at least one additional vaccine dose comprises an unconjugated pneumococcal polysaccharide vaccine composition.
24. The method of claim 19 , wherein the conjugated vaccine is selected from the group consisting of a 7-valent, 9-valent, 10-valent, 11-valent and 13-valent vaccine.
25. The method of claim 19 , wherein the unconjugated polysaccharide vaccine is a 23-valent pneumococcal polysaccharide vaccine.
26. The method of claim 19 , wherein the conjugated vaccine comprises polysaccharides of serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
27. The method of claim 19 , wherein the conjugated vaccine comprises polysaccharides of serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
28. The method of claim 19 , wherein the conjugated vaccine comprises polysaccharides of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9A, 9V, 14, 18C, 19F, and 23F.
29. The method of claim 25 , wherein the unconjugated vaccine comprises polysaccharides of serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
30. The method of claim 22 , wherein the conjugate vaccine comprises polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F.
31. The method of claim 22 , wherein the conjugate vaccine comprises polysaccharides of serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
32. The method of claim 22 , wherein the conjugate vaccine comprises polysaccharides of serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
33. The method of claim 22 , wherein the conjugate vaccine comprises polysaccharides of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9A, 9V, 14, 18C, 19F, and 23F.
34. The method of claim 22 , wherein the polysaccharides are conjugated to a polypeptide carrier.
35. The method of claim 34 , wherein the polypeptide carrier is selected from the group consisting of the meningococcal outer membrane protein complex, CRM 197 , diphtheria toxoid, tetanus toxoid, and protein D from H. influenzae.
36. The method of claim 30 , wherein the conjugate vaccine comprises polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F conjugated to CRM197.